As a large proportion of cats with pancreatitis also have hepatic lipidosis (72, 73), further investigation of the anti-inflammatory effects of FGF21 analogs in cats with pancreatitis and concurrent hepatic lipidosis is needed, particularly since there are very few effective therapeutic options for these conditions, and access to medications that can reduce liver lipid content and reduce pancreatic inflammation could have an important impact on reducing the morbidity and mortality of hospitalized feline patients. The gene discussed is FGF21; the disease is fatty liver disease.